

10

UNITED STATES PATENT APPLICATION  
FOR  
COMPLEX MIXTURES EXHIBITING SELECTIVE INHIBITION OF  
CYCLOOXYGENASE-2

THE COMMISSIONER OF PATENTS AND TRADEMARKS:

20 Your petitioners, **JOHN G. BABISH**, a citizen of the United States, residing at 508  
White Church Rd., Brooktondale, New York 14817; **M. TERRENCE HOWELL**, a citizen  
of the United States, residing at 62 Southworth Road, Dryden, New York 13053 pray that  
letters patent may be granted to them as inventors of the improvement in **COMPLEX**  
**MIXTURES EXHIBITING SELECTIVE INHIBITION OF CYCLOOXYGENASE-2**  
as set forth in the following specification:

## FIELD OF THE INVENTION

The present invention relates generally to a composition comprising a complex mixture of active ingredients exhibiting selective inhibition of inducible cyclooxygenase-2 (COX-2) and method for selective inhibition of COX-2 mediated synthesis of prostaglandins.

More particularly, the composition comprises mixtures of active ingredients isolated from an extract of hops (*Humulus lupulus*). The composition functions to inhibit the inducibility and/or activity of inducible cyclooxygenase (COX-2) with little or no significant effect on constitutive cyclooxygenase (COX-1).

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
2510  
2511  
2512  
2513  
2514  
2515  
2516  
2517  
2518  
2519  
2520  
2521  
2522  
2523  
2524  
2525  
2526  
2527  
2528  
2529  
2530  
2531  
2532  
2533  
2534  
2535  
2536  
2537  
2538  
2539  
2540  
2541  
2542  
2543  
2544  
2545  
2546  
2547  
2548  
2549  
2550  
2551  
2552  
2553  
2554  
2555  
2556  
2557  
2558  
2559  
2560  
2561  
2562  
2563  
2564  
2565  
2566  
2567  
2568  
2569  
2570  
2571  
2572  
2573  
2574  
2575  
2576  
2577  
2578  
2579  
2580  
2581  
2582  
2583  
2584  
2585  
2586  
2587  
2588  
2589  
2590  
2591  
2592  
2593  
2594  
2595  
2596  
2597  
2598  
2599  
25100  
25101  
25102  
25103  
25104  
25105  
25106  
25107  
25108  
25109  
25110  
25111  
25112  
25113  
25114  
25115  
25116  
25117  
25118  
25119  
25120  
25121  
25122  
25123  
25124  
25125  
25126  
25127  
25128  
25129  
25130  
25131  
25132  
25133  
25134  
25135  
25136  
25137  
25138  
25139  
25140  
25141  
25142  
25143  
25144  
25145  
25146  
25147  
25148  
25149  
25150  
25151  
25152  
25153  
25154  
25155  
25156  
25157  
25158  
25159  
25160  
25161  
25162  
25163  
25164  
25165  
25166  
25167  
25168  
25169  
25170  
25171  
25172  
25173  
25174  
25175  
25176  
25177  
25178  
25179  
25180  
25181  
25182  
25183  
25184  
25185  
25186  
25187  
25188  
25189  
25190  
25191  
25192  
25193  
25194  
25195  
25196  
25197  
25198  
25199  
25200  
25201  
25202  
25203  
25204  
25205  
25206  
25207  
25208  
25209  
25210  
25211  
25212  
25213  
25214  
25215  
25216  
25217  
25218  
25219  
25220  
25221  
25222  
25223  
25224  
25225  
25226  
25227  
25228  
25229  
25230  
25231  
25232  
25233  
25234  
25235  
25236  
25237  
25238  
25239  
25240  
25241  
25242  
25243  
25244  
25245  
25246  
25247  
25248  
25249  
25250  
25251  
25252  
25253  
25254  
25255  
25256  
25257  
25258  
25259  
25260  
25261  
25262  
25263  
25264  
25265  
25266  
25267  
25268  
25269  
25270  
25271  
25272  
25273  
25274  
25275  
25276  
25277  
25278  
25279  
25280  
25281  
25282  
25283  
25284  
25285  
25286  
25287  
25288  
25289  
25290  
25291  
25292  
25293  
25294  
25295  
25296  
25297  
25298  
25299  
25300  
25301  
25302  
25303  
25304  
25305  
25306  
25307  
25308  
25309  
25310  
25311  
25312  
25313  
25314  
25315  
25316  
25317  
25318  
25319  
25320  
25321  
25322  
25323  
25324  
25325  
25326  
25327  
25328  
25329  
25330  
25331  
25332  
25333  
25334  
25335  
25336  
25337  
25338  
25339  
25340  
25341  
25342  
25343  
25344  
25345  
25346  
25347  
25348  
25349  
25350  
25351  
25352  
25353  
25354  
25355  
25356  
25357  
25358  
25359  
25360  
25361  
25362  
25363  
25364  
25365  
25366  
25367  
25368  
25369  
25370  
25371  
25372  
25373  
25374  
25375  
25376  
25377  
25378  
25379  
25380  
25381  
25382  
25383  
25384  
25385  
25386  
25387  
25388  
25389  
25390  
25391  
25392  
25393  
25394  
25395  
25396  
25397  
25398  
25399  
25400  
25401  
25402  
25403  
25404  
25405  
25406  
25407  
25408  
25409  
25410  
25411  
25412  
25413  
25414  
25415  
25416  
25417  
25418  
25419  
25420  
25421  
25422  
25423  
25424  
25425  
25426  
25427  
25428  
25429  
25430  
25431  
25432  
25433  
25434  
25435  
25436  
25437  
25438  
25439  
25440  
25441  
25442  
25443  
25444  
25445  
25446  
25447  
25448  
25449  
25450  
25451  
25452  
25453  
25454  
25455  
25456  
25457  
25458  
25459  
25460  
25461  
25462  
25463  
25464  
25465  
25466  
25467  
25468  
25469  
25470  
25471  
25472  
25473  
25474  
25475  
25476  
25477  
25478  
25479  
25480  
25481  
25482  
25483  
25484  
25485  
25486  
25487  
25488  
25489  
25490  
25491  
25492  
25493  
25494  
25495  
25496  
25497  
25498  
25499  
25500  
25501  
25502  
25503  
25504  
25505  
25506  
25507  
25508  
25509  
25510  
25511  
25512  
25513  
25514  
25515  
25516  
25517  
25518  
25519  
25520  
25521  
25522  
25523  
25524  
25525  
25526  
25527  
25528  
25529  
25530  
25531  
25532  
25533  
25534  
25535  
25536  
25537  
25538  
25539  
25540  
25541  
25542  
25543  
25544  
25545  
25546  
25547  
25548  
25549  
25550  
25551  
25552  
25553  
25554  
25555  
25556  
25557  
25558  
25559  
25560  
25561  
25562  
25563  
25564  
25565  
25566  
25567  
25568  
25569  
25570  
25571  
25572  
25573  
25574  
25575  
25576  
25577  
25578  
25579  
25580  
25581  
25582  
25583  
25584  
25585  
25586  
25587  
25588  
25589  
25590  
25591  
25592  
25593  
25594  
25595  
25596  
25597  
25598  
25599  
25600  
25601  
25602  
25603  
25604  
25605  
25606  
25607  
25608  
25609  
25610  
25611  
25612  
25613  
25614  
25615  
25616  
25617  
25618  
25619  
25620  
25621  
25622  
25623  
25624  
25625  
25626  
25627  
25628  
25629  
25630  
25631  
25632  
25633  
25634  
25635  
25636  
25637  
25638  
25639  
25640  
25641  
25642  
25643  
25644  
25645  
25646  
25647  
25648  
25649  
25650  
25651  
25652  
25653  
25654  
25655  
25656  
25657  
25658  
25659  
25660  
25661  
25662  
25663  
25664  
25665  
25666  
25667  
25668  
25669  
25670  
25671  
25672  
25673  
25674  
25675  
25676  
25677  
25678  
25679  
25680  
25681  
25682  
25683  
25684  
25685  
25686  
25687  
25688  
25689  
25690  
25691  
25692  
25693  
25694  
25695  
25696  
25697  
25698  
25699  
25700  
25701  
25702  
25703  
25704  
25705  
25706  
25707  
25708  
25709  
25710  
25711  
25712  
25713  
25714  
25715  
25716  
25717  
25718  
25719  
25720  
25721  
25722  
25723  
25724  
25725  
25726  
25727  
25728  
25729  
25730  
25731  
25732  
25733  
25734  
25735  
25736  
25737  
25738  
25739  
25740  
25741  
25742  
25743  
25744  
25745  
25746  
25747  
25748  
25749  
25750  
25751  
25752  
25753  
25754  
25755  
25756  
25757  
25758  
25759  
25760  
25761  
25762  
25763  
25764  
25765  
25766  
25767  
25768  
25769  
25770  
25771  
25772  
25773  
25774  
25775  
25776  
25777  
25778  
25779  
25780  
25781  
25782  
25783  
25784  
25785  
25786  
25787  
25788  
25789  
25790  
25791  
25792  
25793  
25794  
25795  
25796  
25797  
25798  
25799  
25800  
25801  
25802  
25803  
25804  
25805  
25806  
25807  
25808  
25809  
25810  
25811  
25812  
25813  
25814  
25815  
25816  
25817  
25818  
25819  
25820  
25821  
25822  
25823  
25824  
25825  
25826  
25827  
25828  
25829  
25830  
25831  
25832  
25833  
25834  
25835  
25836  
25837  
25838  
25839  
25840  
25841  
25842  
25843  
25844  
25845  
25846  
25847  
25848  
25849  
25850  
25851  
25852  
25853  
25854  
25855  
25856  
25857  
25858  
25859  
25860  
25861  
25862  
25863  
25864  
25865  
25866  
25867  
25868  
25869  
25870  
25871  
25872  
25873  
25874  
25875  
25876  
25877  
25878  
25879  
25880  
25881  
25882  
25883  
25884  
25885  
25886  
25887  
25888  
25889  
25890  
25891  
25892  
25893  
25894  
25895  
25896  
25897  
25898  
25899  
25900  
25901  
25902  
25903  
25904  
25905  
25906  
25907  
25908  
25909  
25910  
25911  
25912  
25913  
25914  
25915  
25916  
25917  
25918  
25919  
25920  
25921  
25922  
25923  
25924  
25925  
25926  
25927  
25928  
25929  
25930  
25931  
25932  
25933  
25934  
25935  
25936  
25937  
25938  
25939  
25940  
25941  
25942  
25943  
25944  
25945  
25946  
25947  
25948  
25949  
25950  
25951  
25952  
25953  
25954  
25955  
25956  
25957  
25958  
25959  
25960  
25961  
25962  
25963  
25964  
25965  
25966  
25967  
25968  
25969  
25970  
25971  
25972  
25973  
25974  
25975  
25976  
25977  
25978  
25979  
25980  
25981  
25982  
25983  
25984  
25985  
25986  
25987  
25988  
25989  
25990  
25991  
25992  
25993  
25994  
25995  
25996  
25997  
25998  
25999  
25100  
25101  
25102  
25103  
25104  
25105  
25106  
25107  
25108  
25109  
25110  
25111  
25112  
25113  
25114  
25115  
25116  
25117  
25118  
25119  
25120  
25121  
25122  
25123  
25124  
25125  
25126  
25127  
25128  
25129  
25130  
25131  
25132  
25133  
25134  
25135  
25136  
25137  
25138  
25139  
25140  
25141  
25142  
25143  
25144  
25145  
25146  
25147  
25148  
25149  
25150  
25151  
25152  
25153  
25154  
25155  
25156  
25157  
25158  
25159  
25160  
25161  
25162  
25163  
25164  
25165  
25166  
25167  
25168  
25169  
25170  
25171  
25172  
25173  
25174  
25175  
25176  
25177  
25178  
25179  
25180  
25181  
25182  
25183  
25184  
25185  
25186  
25187  
25188  
25189  
25190  
25191  
25192  
25193  
25194  
25195  
25196  
25197  
25198  
25199  
25200  
25201  
25202  
25203  
25204  
25205  
25206  
25207  
25208  
25209  
25210  
25211  
25212  
25213  
25214  
25215  
25216  
25217  
25218  
25219  
25220  
25221  
25222  
25223  
25224  
25225  
25226  
25227  
25228  
25229  
25230  
25231  
25232  
25233  
25234  
25235  
25236  
25237  
25238  
25239  
25240  
25241  
25242  
25243  
25244  
25245  
25246  
25247  
25248  
25249  
25250  
25251  
25252  
25253  
25254  
25255  
25256  
25257  
25258  
25259  
25260  
25261  
25262  
25263  
25264  
25265  
25266  
25267  
25268  
25269  
25270  
25271  
25272  
25273  
25274  
25275  
25276  
25277  
25278  
25279  
25280  
25281  
25282  
25283  
25284  
25285  
25286  
25287  
25288  
25289  
25290  
25291  
25292  
25293  
25294  
25295  
25296  
25297  
25298  
25299  
252100  
252101  
252102  
252103  
252104  
252105  
252106  
252107  
252108  
252109  
252110  
252111  
252112  
252113  
252114  
252115  
252116  
252117  
252118  
252119  
252120  
252121  
252122  
252123  
252124  
252125  
252126  
252127  
252128  
252129  
252130  
252131  
252132  
252133  
252134  
252135  
252136  
252137  
252138  
252139  
252140  
252141  
252142  
252143  
252144  
252145  
252146  
252147  
252148  
252149  
252150  
252151  
252152  
252153  
252154  
252155  
252156  
252157  
252158  
252159  
252160  
252161  
252162  
252163  
252164  
252165  
252166  
252167  
252168  
252169  
252170  
252171  
252172  
252173  
252174  
252175  
252176  
252177  
252178  
252179  
252180  
252181  
252182  
252183  
252184  
252185  
252186  
252187  
252188  
252189  
252190  
252191  
252192  
252193  
252194  
252195  
252196  
252197  
252198  
252199  
252200  
252201  
252202  
252203  
252204  
252205  
252206  
252207  
252208  
252209  
252210  
252211  
252212  
252213  
252214  
252215  
252216  
252217  
252218  
252219  
252220  
252221  
252222  
252223  
252224  
252225  
252226  
252227  
252228  
252229  
252230  
252231  
252232  
252233  
252234  
252235  
252236  
252237  
252238  
252239  
252240  
252241  
252242  
252243  
252244  
252245  
252246  
252247  
252248  
252249  
252250  
252251  
252252  
252253  
252254  
252255  
252256  
252257  
252258  
252259  
252260  
252261  
252262  
252263  
252264  
252265  
252266  
252267  
252268  
252269  
252270  
252271  
252272  
252273  
252274  
252275  
252276  
252277  
252278  
252279  
252280  
252281  
252282  
252283  
252284  
252285  
252286  
252287  
252288  
252289  
252290  
252291  
252292  
252293  
252294  
252295  
252296  
252297  
252298  
252299  
252300  
252301  
252302  
252303  
252304  
252305  
252306  
252307  
252308  
252309  
252310  
252311  
252312  
252313  
252314  
252315  
252316  
252

5 control of cell growth. While COX-2 is inducible in many tissues, it is present  
constitutively in the brain and spinal cord, where it may function in nerve transmission  
for pain and fever. The two isoforms of COX are nearly identical in structure but have  
important differences in substrate and inhibitor selectivity and in their intracellular  
locations. Protective PGs, which preserve the integrity of the stomach lining and  
10 maintain normal renal function in a compromised kidney, are synthesized by COX-1. On  
the other hand, PGs synthesized by COX-2 in immune cells are central to the  
inflammatory process.

The discovery of COX-2 has made possible the design of drugs that reduce  
inflammation without removing the protective PGs in the stomach and kidney made by  
15 COX-1. Combinations of the invention would be useful for, but not limited to, the  
treatment of inflammation in a subject, and for treatment of other inflammation-  
associated disorders, such as, as an analgesic in the treatment of pain and headaches, or as  
an antipyretic for the treatment of fever. For example, combinations of the invention  
would be useful to treat arthritis, including but not limited to rheumatoid arthritis,  
20 spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus, and  
juvenile arthritis. Such combination of the invention would be useful in the treatment of  
asthma, bronchitis, menstrual cramps, tendonitis, bursitis, and skin related conditions  
such as psoriasis, eczema, burns and dermatitis. Combinations of the invention also  
would be useful to treat gastrointestinal conditions such as inflammatory bowel disease,  
25 Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis and for the  
prevention or treatment of cancer such as colorectal cancer. Compositions of the  
invention would be useful in treating inflammation in such diseases as vascular diseases,

5 migraine headaches, periarthritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, sclerodema, rheumatic fever, type I diabetes, myasthenia gravis, multiple sclerosis, sacoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, hypersensitivity, swelling occurring after injury, myocardial ischemia and the like.

The compositions of the present invention would also be useful in the treatment of 10 ophthalmic diseases, such as retinopathies, conjunctivitis, uveitis, ocular photophobia, and of acute injury to the eye tissue. The compounds would also be useful in the treatment of pulmonary inflammation, such as that associated with viral infections and 15 cystic fibrosis. The compounds would also be useful for the treatment of certain nervous system disorders such as cortical dementias including Alzheimer's disease. The combinations of the invention are useful as anti-inflammatory agents, such as for the 20 treatment of arthritis, with the additional benefit of having significantly less harmful side effects. As inhibitors of COX-2 mediated biosynthesis of PGE2, these compositions would also be useful in the treatment of allergic rhinitis, respiratory distress syndrome, endotoxin shock syndrome, atherosclerosis, and central nervous system damage resulting from stroke, ischemia and trauma.

Besides being useful for human treatment, these compounds are also useful for 25 treatment of other animals, including horses, dogs, cats, birds, sheep, pigs, etc. An ideal formulation for the treatment of inflammation would inhibit the induction and activity of COX-2 without affecting the activity of COX-1. Historically, the non-steroidal and steroidal anti-inflammatory drugs used for treatment of inflammation lack the specificity of inhibiting COX-2 without affecting COX-1. Therefore, most anti-inflammatory drugs damage the gastrointestinal system when used for extended periods. Thus, new COX-2

specific treatments for inflammation and inflammation-based diseases are urgently needed.

Hop extraction in one form or another goes back over 150 years to the early nineteenth century when extraction in water and ethanol was first attempted. Even today an ethanol extract is available in Europe, but by far the predominant extracts are organic solvent extracts (hexane) and CO<sub>2</sub> extracts (supercritical and liquid). CO<sub>2</sub> (typically at 60 bars pressure and 5 to 10°C) is in a liquid state and is a relatively mild, non-polar solvent highly specific for hop soft resins and oils. Beyond the critical point, typically at 300 bars pressure and 60°C, CO<sub>2</sub> has the properties of both a gas and a liquid and is a much stronger solvent. The composition of the various extracts is compared in Table 1.

Table 1. Hop Extracts (Percent W/W)

<b>Component</b>	<b>Hops</b>	<b>Organic Solvent Extract</b>	<b>Super-Critical CO<sub>2</sub></b>	<b>Liquid CO<sub>2</sub></b>
Total resins	12 - 20	15 - 60	75 - 90	70 - 95
Alpha-acids	2 - 12	8 - 45	27 - 55	30 - 60
Beta-acids	2 - 10	8 - 20	23 - 33	15 - 45
Essential oils	0.5 - 1.5	0 - 5	1 - 5	2 - 10
Hard resins	2 - 4	2 - 10	5 - 11	None
Tannins	4 - 10	0.5 - 5	0.1 - 5	None
Waxes	1 - 5	1 - 20	4 - 13	0 - 10
Water	8 - 12	1 - 15	1 - 7	1 - 5

At its simplest, hop extraction involves milling, pelleting and re-milling the hops to spread the lupulin, passing a solvent through a packed column to collect the resin components and finally, removal of the solvent to yield a whole or "pure" resin extract.

5

The main organic extractants are strong solvents and in addition to virtually all the lupulin components, they extract plant pigments, cuticular waxes, water and water-soluble materials.

10

Supercritical CO<sub>2</sub> is more selective than the organic solvents and extracts less of the tannins and waxes and less water and hence water-soluble components. It does extract some of the plant pigments like chlorophyll but rather less than the organic solvents do. Liquid CO<sub>2</sub> is the most selective solvent used commercially for hops and hence produces the most pure whole resin and oil extract. It extracts none of the hard resins or tannins, much lower levels of plant waxes, no plant pigments and less water and water-soluble materials.

20

As a consequence of this selectivity and the milder solvent properties, the absolute yield of liquid CO<sub>2</sub> extract per unit weight of hops is less than when using the other mentioned solvents. Additionally, the yield of alpha acids with liquid CO<sub>2</sub> (89 - 93%) is lower than that of supercritical CO<sub>2</sub> (91 - 94%) or the organic solvents (93 - 96%). Following extraction there is the process of solvent removal, which for organic solvents involves heating to cause volatilization. Despite this, trace amounts of solvent do remain in the extract. The removal of CO<sub>2</sub>, however, simply involves a release of pressure to volatilize the CO<sub>2</sub>.

25

The identification of humulone from hops extract as an inhibitor of bone resorption is reported in Tobe, H. et al. 1997. Bone resorption Inhibitors from hop extract. Biosci. Biotech. Biochem 61(1)158-159. Later studies by the same group characterized the mechanism of action of humulone as inhibition of COX-2 gene transcription following TNFalpha stimulation of MC3T3 -E1 cells [Yamamoto, K. 2000. Suppression

5 of cyclooxygenase-2 gene transcription by humulon of bee hop extract studied with  
reference to glucocorticoid. FEBS Letters 465:103-106].

Thus, it would be useful to identify a natural formulation of compounds that  
would specifically inhibit or prevent the synthesis of prostaglandins by COX-2 with little  
or no effect on COX-1. Such a formulation, which would be useful for preserving the  
10 health of joint tissues, for treating arthritis or other inflammatory conditions, has not  
previously been discovered. The term "specific or selective COX-2 inhibitor" embrace  
compounds or mixtures of compounds that selectively inhibit COX-2 over COX-1.  
Preferably, the compounds have a median effective concentration for COX-2 inhibition  
that is minimally five times greater than the median effective concentration for the  
15 inhibition of COX-1. For example, if the median inhibitory concentration for COX-2 of a  
test formulation was 0.2 µg/mL, the formulation would not be considered COX-2 specific  
unless the median inhibitory concentration for COX-1 was equal to or greater than 1  
µg/mL.

While glucosamine is generally accepted as being effective and safe for treating  
20 osteoarthritis, medical intervention into the treatment of degenerative joint diseases is  
generally restricted to the alleviation of its acute symptoms. Medical doctors generally  
utilize non-steroidal and steroidal anti-inflammatory drugs for treatment of osteoarthritis.  
These drugs, however, are not well adapted for long-term therapy because they not only  
lack the ability to promote and protect cartilage; they can actually lead to degeneration of  
25 cartilage or reduction of its synthesis. Moreover, most non-steroidal, anti-inflammatory

5 drugs damage the gastrointestinal system when used for extended periods. Thus, new treatments for arthritis are urgently needed.

The joint-protective properties of glucosamine would make it an attractive therapeutic agent for osteoarthritis except for two drawbacks: (1) the rate of response to glucosamine treatment is slower than for treatment with anti-inflammatory drugs, and (2) glucosamine may fail to fulfill the expectation of degenerative remission. In studies comparing glucosamine with non-steroidal anti-inflammatory agents, for example, a double-blinded study comparing 1500 mg glucosamine sulfate per day with 1200 mg ibuprofen, demonstrated that pain scores decreased faster during the first two weeks in the ibuprofen patients than in the glucosamine-treated patients. However, the reduction in pain scores continued throughout the trial period in patients receiving glucosamine and the difference between the two groups turned significantly in favor of glucosamine by week eight. Lopes Vaz, A., Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthritis of the knee in outpatients, 8 Curr. Med Res Opin. 145-149 (1982). Thus, glucosamine may relieve the pain and inflammation of arthritis at a slower rate than the available anti-inflammatory drugs.

An ideal formulation for the normalization of cartilage metabolism or treatment of osteoarthritis would provide adequate chondroprotection with potent anti-inflammatory activity. The optimal dietary supplement for osteoarthritis should enhance the general joint rebuilding qualities offered by glucosamine and attenuate the inflammatory response

5 without introducing any harmful side effects. It should be inexpensively manufactured  
and comply with all governmental regulations.

However, the currently available glucosamine formulations have not been  
formulated to optimally attack and alleviate the underlying causes of osteoarthritis and  
rheumatoid arthritis. Moreover, as with many commercial herbal and dietary  
10 supplements, the available formulations do not have a history of usage, nor controlled  
clinical testing, which might ensure their safety and efficacy.

Therefore, it would be useful to identify a composition that would specifically  
inhibit or prevent the expression of COX-2 enzymatic activity, while having little or no  
effect on COX-1 metabolism so that these could be used at sufficiently low doses or at  
15 current clinical doses with no adverse side effects.

#### SUMMARY OF THE INVENTION

The present invention provides a composition comprising an effective amount of  
component I selected from the group consisting of alpha acids and beta acids and an  
effective amount of at least one component II selected from the group consisting of alpha  
20 acids, beta acids, essential oils, fats and waxes, with the proviso that component I and II  
are not the same compound. Preferably, the composition comprises two or more active  
ingredients selected from the group consisting of  $\alpha$ -acid,  $\beta$ -acid and essential oil. The  
active ingredients of the present invention are preferably made from hops extract. The  
25 composition functions synergistically to inhibit the activity of inducible COX-2 with little  
or no effect on COX-1.

The present invention further provides a composition of matter that enhances the function of glucosamine or chondroitin sulfate to normalize joint movement or reduce the symptoms of osteoarthritis.

One specific embodiment of the present invention is a composition comprising a 30 to 60 weight percent of  $\alpha$ -acid, 15 to 45 weight percent of  $\beta$ -acid and 3 to 6 weight percent of essential oil. The composition optionally comprises 2 to 8 weight percent of fats and waxes. Preferably, the  $\alpha$ -acid,  $\beta$ -acid, essential oil, fats or waxes are from a hops extract, which is preferably prepared by CO<sub>2</sub> extraction.

The present invention further provides a method of dietary supplementation and a method of treating inflammation or inflammation-based diseases in an animal which comprises providing to the animal suffering symptoms of inflammation, including pain and swelling, the composition of the present invention containing two or more active ingredients selected from the group consisting of  $\alpha$ -acid,  $\beta$ -acid and essential oil and continuing to administer such a dietary supplementation of the composition until said symptoms are eliminated or reduced.

#### DETAILED DESCRIPTION OF THE INVENTION

Before the present composition and methods of making and using thereof are disclosed and described, it is to be understood that this invention is not limited to the particular configurations, as process steps, and materials may vary somewhat. It is also intended to be understood that the terminology employed herein is used for the purpose of describing particular embodiments only and is not intended to be limiting since the scope

5 of the present invention will be limited only by the appended claims and equivalents thereof.

It must be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

10 The present invention provides a composition having a selective inhibitory effect on the activity of COX-2, said composition comprising an effective amount of component I selected from the group consisting of alpha acids and beta acids and an effective amount of at least one component II selected from the group consisting of alpha acids, beta acids, essential oils, fats and waxes, with the proviso that component I and II are not the same compound. More particularly, the composition comprises two or more active ingredients selected from the groups consisting of  $\alpha$ -acids,  $\beta$ -acids and essential oils. Preferably, the active ingredients of the present invention are made from Hops extract. Preferably, composition comprising an 30 to 60 weight percent of  $\alpha$ -acids, 15 to 45 weight percent of  $\beta$ -acids and 3 to 6 weight percent of essential oils. The composition optionally comprises 15 20 2 to 8 weight percent of fats and waxes. Preferably, the  $\alpha$ -acids,  $\beta$ -acids, essential oils, fats or waxes are from a hop extract, which is preferably prepared by CO<sub>2</sub> extraction. The composition provided by the present invention can be formulated as a dietary supplement or therapeutic composition. The composition functions to inhibit the inducibility and/or activity of COX-2 with little or no effect on COX-1.

As used herein, the term "dietary supplement" refers to compositions consumed to affect structural or functional changes in physiology. The term "therapeutic composition" refers to any compounds administered to treat or prevent a disease.

As used herein, the term "COX inhibitor" refers to a composition of natural compounds that is capable of inhibiting the activity or expression of COX-2 enzymes or is capable of inhibiting or reducing the severity, including pain and swelling, of a severe inflammatory response.

As used herein, the term "hop extract" refers to the solid material resulting from (1) exposing a hops plant product to a solvent, (2) separating the solvent from the hops plant product, and (3) eliminating the solvent.

As used herein, the term "solvent" refers to a liquid of aqueous or organic nature possessing the necessary characteristics to extract solid material from the hop plant product. Examples of solvents would include water, steam, superheated water, methanol, ethanol, hexane, chloroform, liquid CO<sub>2</sub>, liquid N<sub>2</sub> or any combinations of such materials.

As used herein, the term "CO<sub>2</sub> extract" refers to the solid material resulting from exposing a hops plant product to a liquid or supercritical CO<sub>2</sub> preparation followed by the removing the CO<sub>2</sub>.

As used herein, the term " $\alpha$ -acid fraction" refers to compounds isolated from hops plant products including, among others, humulone, cohumulone, isohumulone, isoprehumulone, hulupone, adhumulone, xanthohumol A and xanthohumol B.

5 As used herein, the term " $\beta$ -acid fraction" refers to compounds collectively known  
as lupulones including among others lupulone, colupulone, adlupulone,  
tetrahydroisohumulone, and hexahydrocolupulone,

10 As used herein, the term "essential oil fraction" refers to a complex mixture of  
components consisting chiefly of myrcene, humulene, beta-caryophyleen, undecane-2-on,  
and 2-methyl-but-3-en-ol.

As used herein, the term "fats" refers to triacylglycerol esters of fatty acids.

15 As used herein, the term "waxes" refers to triacylglycerol ethers or esters of  
extremely long chain (>25 carbons) fatty alcohols or acids.

Therefore, one preferred embodiment of the present invention is a composition  
comprising a combination of an effective amount of two or more active ingredients  
selected from the group consisting of  $\alpha$ -acid,  $\beta$ -acid and essential oil. The composition of  
the present invention functions to specifically inhibit the inducibility and/or activity of  
COX-2 while showing little or no effect on COX-1. Therefore, the composition of the  
present invention essentially eliminates the inflammatory response, including pain and  
swelling, rapidly without introducing any harmful side effects.

20 The pharmaceutical grade extract must pass extensive safety and efficacy  
procedures. Pharmaceutical grade CO<sub>2</sub> hops extract refers to a preparation wherein the  
concentration of hops extract, as employed in the practice of the invention, has an  $\alpha$ -acid  
content of about 10 to 95 percent by weight. Preferably, the  $\alpha$ -acid content is greater than  
45 percent by weight. The range of  $\beta$ -acid content in a pharmaceutical grade hops extract

25

5 is about 10 to 95 percent by weight. Preferably, the  $\beta$ -acid content is greater than 45 percent by weight. The pharmaceutical grade extracts are particularly preferred. A daily dose (mg/kg-day) of the present dietary supplement would be formulated to deliver, about 0.001 to 100 mg CO<sub>2</sub> extract of hops extract per kg body weight of the animal.

10 The composition of the present invention for topical application would contain about 0.001 to 10 wt%, preferably 0.01 to 1 wt% of pharmaceutical grade CO<sub>2</sub> hops extract.

The preferred composition of the present invention would produce serum or target tissue concentrations of any of the  $\alpha$ -acid or  $\beta$ -acid components in the range of about 0.005 to 10,000 ng/mL.

15 In addition to the combination of component I selected from the group consisting of alpha acids and beta acids and at least one component II selected from the group consisting of alpha acids, beta acids, essential oils, fats and waxes, with the proviso that component I and II are not the same compound, the present composition for dietary application may include various additives such as other natural components of intermediary metabolism, vitamins and minerals, as well as inert ingredients such as talc and magnesium stearate that are standard excipients in the manufacture of tablets and capsules.

20 As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, isotonic and absorption delaying agents, sweeteners and the like. These pharmaceutically acceptable carriers may be prepared from a wide range of materials including, but not limited to, diluents, binders and adhesives,

5 lubricants, disintegrants, coloring agents, bulking agents, flavoring agents, sweetening  
agents and miscellaneous materials such as buffers and absorbents that may be needed in  
order to prepare a particular therapeutic composition. The use of such media and agents  
for pharmaceutically active substances is well known in the art. Except insofar as any  
conventional media or agent is incompatible with the active ingredients, its use in the  
10 present composition is contemplated. In one embodiment, talc and magnesium stearate  
are included in the present formulation. Other ingredients known to affect the  
manufacture of this composition as a dietary bar or functional food can include  
flavorings, sugars, amino-sugars, proteins and/or modified starches, as well as fats and  
oils.

15 The dietary supplements, lotions or therapeutic compositions of the present  
invention can be formulated in any manner known by one of skill in the art. In one  
embodiment, the composition is formulated into a capsule or tablet using techniques  
available to one of skill in the art. In capsule or tablet form, the recommended daily dose  
for an adult human or animal would preferably be contained in one to six capsules or  
20 tablets. However, the present compositions may also be formulated in other convenient  
forms, such as an injectable solution or suspension, a spray solution or suspension, a  
lotion, gum, lozenge, food or snack item. Food, snack, gum or lozenge items can include  
any ingestible ingredient, including sweeteners, flavorings, oils, starches, proteins, fruits  
or fruit extracts, vegetables or vegetable extracts, grains, animal fats or proteins. Thus,  
25 the present compositions can be formulated into cereals, snack items such as chips, bars,  
chewable candies or slowly dissolving lozenges.

5           The present invention contemplates treatment of all types of inflammation-based

diseases, both acute and chronic. The present formulation reduces the inflammatory response and thereby promotes healing of, or prevents further damage to, the affected tissue. A pharmaceutically acceptable carrier may also be used in the present compositions and formulations.

10           According to the present invention, the animal may be a member selected from

the group consisting of humans, non-human primates, such as dogs, cats, birds, horses, ruminants or other animals. The invention is directed primarily to the treatment of human beings. Administration can be by any method available to the skilled artisan, for example, by oral, topical, transdermal, transmucosal, or parenteral routes.

15           The following examples are intended to illustrate but not in any way limit the invention.

#### EXAMPLE 1

20           Selective Inhibition of Cyclooxygenase-2 Mediated Prostaglandin E2

by a CO<sub>2</sub> Extract of Hops

This example illustrates a superior COX-2 selectivity of the CO<sub>2</sub> hops extract of the present invention compared to the pure compound humulone described in the prior art. Therefore it is to be inferred that the effectiveness of the CO<sub>2</sub> hops extract of the present invention would be superior to the pure compound humulone described in the prior art.

Inhibition of COX-2 Mediated Production of PGE2 by CO<sub>2</sub> extract of Hops

Equipment - balancer, analytical, Ohaus Explorer (Ohaus Model #EO1140, Switzerland), biosafety cabinet (Forma Model #F1214, Marietta, Ohio), pipettor, 100 to 1000 µL (VWR Catalog #4000-208, Rochester, NY), cell hand tally counter (VWR Catalog #23609-102, Rochester, NY), CO<sub>2</sub> incubator (Forma Model #F3210, Marietta, Ohio), hemacytometer (Hausser Model #1492, Horsham, PA), microscope, inverted (Leica Model #DM IL, Wetzlar, Germany), multichannel pipettor, 12-Channel (VWR Catalog #53501-662, Rochester, NY), Pipet Aid (VWR Catalog #53498-103, Rochester, NY), Pipettor, 0.5 to 10 µL (VWR Catalog #4000-200, Rochester, NY), pipettor, 100 to 1000 µL (VWR Catalog #4000-208, Rochester, NY), pipettor, 2 to 20 µL (VWR Catalog #4000-202, Rochester, NY), pipettor, 20 to 200 µL (VWR Catalog #4000-204, Rochester, NY), PURELAB Plus Water Polishing System (U.S. Filter, Lowell, MA), refrigerator, 4°C (Forma Model #F3775, Marietta, Ohio), vortex mixer (VWR Catalog #33994-306, Rochester, NY), water bath (Shel Lab Model #1203, Cornelius, OR).

Cells, Chemicals, Reagents and Buffers - Cell scrapers (Corning Catalog #3008, Corning, NY), dimethylsulfoxide (DMSO) (VWR Catalog #5507, Rochester, NY), Dulbecco's Modification of Eagle's Medium (DMEM) (Mediatech Catalog #10-013-CV, Herndon, VA), fetal bovine serum, heat inactivated (FBS-HI) (Mediatech Catalog #35-011-CV, Herndon, VA), lipopolysaccharide (LPS)(Sigma Catalog #L-2654, St. Louis, MO), microfuge tubes, 1.7 mL (VWR Catalog #20172-698, Rochester, NY),

5 penicillin/streptomycin (Mediatech Catalog #30-001-CI, Herndon, VA), pipet tips for 0.5  
to 10  $\mu$ L pipettor (VWR Catalog #53509-138, Rochester, NY), pipet tips for 100-1000  
 $\mu$ L pipettor (VWR Catalog #53512-294, Rochester, NY), pipet tips for 2-20  $\mu$ L and 20-  
200  $\mu$ L pipettors (VWR Catalog #53512-260, Rochester, NY), pipets, 10 mL (Becton  
Dickinson Catalog #7551, Marietta, OH), pipets, 2 mL (Becton Dickinson Catalog #7507,  
10 Marietta, OH, pipets, 5 mL (Becton Dickinson Catalog #7543, Marietta, OH), RAW  
264.7 Cells (American Type Culture Collection Catalog #TIB-71, Manassas, VA), test  
compounds (liquid CO<sub>2</sub> hops extract from Hopunion, Yakima, WA), tissue culture plates,  
96-well (Becton Dickinson Catalog #3075, Franklin Lanes, NJ), Ultra-pure water  
(Resistance =18 megaOhm-cm deionized water).

15 ***General Procedure*** - RAW 264.7 cells, obtained from ATCC, were grown in DMEM  
medium and maintained in log phase. The DMEM growth medium was made as follows :  
50 mL of heat inactivated FBS and 5 mL of penicillin/streptomycin was added to a 500 mL  
bottle of DMEM and stored at 4°C. For best result the medium is to be used within three  
months and warmed to 37°C in water bath before use.

20 On day one of the experiment, the log phase 264.7 cells were plated at  $8 \times 10^4$  cells  
per well in 0.2 mL growth medium per well in a 96-well tissue culture plate in the morning.  
At the end of the day 1 (6 to 8 hours post plating), 100  $\mu$ L of growth medium from each well  
were removed and replaced with 100  $\mu$ L fresh medium. A 1.0 mg/mL solution of LPS, which  
is used to induce the expression of COX-2 in the RAW 264.7 cells, was prepared by  
dissolving 1.0 mg of LPS in 1 mL DMSO. It was vortexed until it dissolved and was stored  
25

5 at 4 °C. Melt at room temperature or in a 37 °C water bath before use. Make up a new  
solution every 60 days.

On day two of the experiment, liquid CO<sub>2</sub> hops extract was prepared as 1000X stock  
in DMSO. For example, if the final concentration of the test material is to be 10 µg/mL, a  
10 mg/mL stock should be prepared by dissolving 10 mg of the test material in 1 mL of  
DMSO. For the best result, fresh liquid CO<sub>2</sub> hops extract should be prepared on the day of  
the experiment. In 1.7 mL microfuge tubes, 1 mL DMEM without FBS was added for test  
concentrations of 0.05, 0.10, 0.5, and 1.0 µg/mL. 2 µL of the 1000X DMSO stock of the test  
material was added to the 1 mL of medium without FBS. The tube contained the final  
concentration of the test material concentrated 2-fold and then placed in an incubator for 10  
minutes to equilibrate.

One-hundred microliters of medium was removed from each well of the cell plates  
prepared on day one. One-hundred microliter of equilibrated 2X final concentration the test  
compounds was added to cells and incubated for 90 minutes. LPS in DMEM without FBS  
was prepared by adding 44 µL of the 1 mg/mL DMSO stock to 10 mL of medium. For each  
20 well of cells to be stimulated, 20 µL of LPS (final concentration of LPS is 0.4 µg/mL of LPS)  
was added and incubated for 24 hours.

On day 3, the appearance of the cells was observed. One-hundred microliter  
supernatent medium from each well was transferred to a clean microfuge tube for the  
determination of amount of PGE2 in the medium.

### Determination of COX-1 Enzyme Inhibition by Hops Extract

The ability of a test material to inhibit COX-1 synthesis of PGE2 was determined essentially as described by Noreen, Y., et al. (*J. Nat. Prod.* 61, 2-7, 1998).

**Equipment** - balancer (2400 g, Acculab VI-2400, VWR Catalog #11237-300, Rochester, NY), balancer, analytical, Ohaus Explorer (Ohaus Model #EO1140, Switzerland), biosafety cabinet (Forma Model #F1214, Marietta, Ohio), Freezer, -30°C (Forma Model #F3797), Freezer, -80°C Ultralow (Forma Model #F8516, Marietta, OH), heated stirring plate (VWR Catalog #33918-262, Rochester, NY), ice maker (Scotsman Model #AFE400A-1A, Fairfax, SC), multichannel pipettor, 12-Channel (VWR Catalog #53501-662, Rochester, NY), Multichannel Pipettor, 8-Channel (VWR Catalog #53501-660, Rochester, NY), orbital shaker platform (Scienceware #F37041-0000, Pequannock, NJ), pH meter (VWR Catalog #33221-010, Rochester, NY), pipet aid (VWR Catalog #53498-103, Rochester, NY), pipettor, 0.5 to 10 µL (VWR Catalog #4000-200, Rochester, NY), pipettor, 100 to 1000 µL (VWR Catalog #4000-208, Rochester, NY), pipettor, 2 to 20 µL (VWR Catalog #4000-202, Rochester, NY), pipettor, 20 to 200 µL (VWR Catalog #4000-204, Rochester, NY), PURELAB Plus Water Polishing System (U.S. Filter, Lowell, MA), refrigerator, 4°C (Forma Model #F3775, Marietta, Ohio), vacuum chamber (Sigma Catalog #Z35, 407-4, St. Louis, MO), vortex mixer (VWR Catalog #33994-306, Rochester, NY)

**Supplies and Reagents** - 96-Well, round-bottom plate (Nalge Nunc #267245, Rochester, NY), arachidonic acid (Sigma Catalog #A-3925, St. Louis, MO), centrifuge tubes, 25 15 mL, conical, sterile (VWR Catalog #20171-008, Rochester, NY), COX-1 enzyme (ovine)

5           40,000 units/mg (Cayman Chemical Catalog #60100, Ann Arbor, MI), dimethylsulfoxide  
(DMSO) (VWR Catalog #5507, Rochester, NY), ethanol 100% (VWR Catalog #MK701908,  
Rochester, NY), epinephrine (Sigma Catalog #E-4250, St. Louis, MO), glutathione (reduced)  
(Sigma Catalog # G-6529, St. Louis, MO), graduated cylinder, 1000 mL (VWR Catalog  
#24711-364, Rochester, NY), hematin (porcine) (Sigma catalog # H-3281, St. Louis, MO),  
10          hydrochloric acid (HCl) (VWR Catalog #VW3110-3, Rochester, NY), KimWipes (Kimberly  
Clark Catalog #34256, Roswell, GA), microfuge tubes, 1.7 mL (VWR Catalog #20172-698,  
Rochester, NY), NaOH (Sigma Catalog #S-5881, St. Louis, MO), pipet tips for 0.5 to 10 µL  
15          pipettor (VWR Catalog #53509-138, Rochester, NY), pipet tips for 100-1000 µL pipettor  
(VWR Catalog #53512-294, Rochester, NY), pipet tips for 2-20 µL and 20-200 µL pipettors  
(VWR Catalog #53512-260, Rochester, NY), prostaglandin E2 (Sigma Catalog # P-5640,  
St. Louis, MO), prostaglandin F2alpha (Sigma Catalog # P-0424, St. Louis, MO), stir bar,  
magnetic (VWR Catalog #58948-193, Rochester, NY), storage bottle, 1000 mL (Corning  
Catalog #1395-1L, Corning, NY), storage bottle, 100 mL (Corning Catalog #1395-100,  
Corning, NY), CO<sub>2</sub> extract of hops (Hopunion, Yakima, WA), Tris-HCl (Sigma Catalog #T-  
20          5941, St. Louis, MO), ultra-pure water (Resistance =18 megaOhm-cm deionized water).  
25          

***General Procedure*** - Oxygen-free 1.0M Tris-HCl buffer (pH 8.0) was prepared as follows: In a 1000 mL beaker, 12.11g Trizma HCl was dissolved into 900 mL ultra-pure water. The beaker was placed on a stir plate with a stir bar. NaOH was added until the pH reached 8.0. The volume was adjusted to a final volume of 1000mL and stored in a 1000 mL storage bottle.

5           The Tris-HCl buffer was placed into a vacuum chamber with a loose top and the air  
pump was turned on until the buffer stopped bubbling. The vacuum chamber was turned off  
and the storage bottle was covered tight. This step was repeated each time when the oxygen-  
free Tris-HCl buffer was used.

10          1 mL cofactor solution was prepared by adding 1.3 mg (-) epinephrine, 0.3 mg  
reduced glutathione and 1.3 mg hematin to 1 mL oxygen free Tris-HCl buffer. Solutions of  
the test material were prepared as needed. i.e. 10 mg of aspirin was weighed and dissolved  
into 1 mL DMSO.

15          Enzyme was dissolved in oxygen free Tris-HCl buffer as follows, i.e. on ice, 6.5  $\mu$ L  
of enzyme at 40,000 units/mL was taken and added to 643.5  $\mu$ L of oxygen free Tris-HCl  
buffer. This enzyme solution is enough for 60 reactions. The COX-1 enzyme solution was  
prepared as follows. in a 15 mL centrifuge tube, 10  $\mu$ L COX-1 enzyme at 40,000 units/mL  
was added in oxygen free Tris-HCl with 50  $\mu$ L of the cofactor solution per reaction. The  
mixture was incubated on ice for 5 minutes (i.e. for 60 reactions add 650  $\mu$ l enzyme in  
oxygen free Tris-HCl buffer with 3.25 mL cofactor solution).

20          60  $\mu$ l of the enzyme solution was combined with 20  $\mu$ l of the test solution in each  
well of a 96 well plate. Final concentrations of the test solutions were 100, 50, 25, 12.5, 6.25  
and 3.12  $\mu$ g/mL. The plates were preincubated on ice for 10 minutes. 20  $\mu$ L arachidonic  
acid (30 $\mu$ M) was added and incubated for 15 minutes at 37°C.

25          2 M HCl was prepared by diluting 12.1 N HCl. In a 100 mL storage bottle, 83.5 mL  
ultra-pure water was added and then 16.5 mL 12.1 N HCl was added. It was stored in a 100

5 mL storage bottle and placed in the biosafety cabinet (always add acid last). The reaction was terminated by adding 10 µL 2 M HCl. The final solution was used as the supernate for the PGE<sub>2</sub> assay.

Determination of PGE2 Concentration in Medium -

The procedure followed was that essentially described by Hamberg, M. and 10 Samuelsson, B. (*J. Biol. Chem.* 1971. 246, 6713-6721); however a commercial, nonradioactive procedure was employed.

**Equipment** - freezer, -30°C (Forma Model #F3797), heated stirring plate (VWR Catalog #33918-262, Rochester, NY), multichannel pipettor, 12-Channel (VWR Catalog #53501-662, Rochester, NY), orbital shaker platform (Scienceware #F37041-0000, Pequannock, NJ), Pipet Aid (VWR Catalog #53498-103, Rochester, NY), pipettor, 0.5 to 10 µL (VWR Catalog #4000-200, Rochester, NY), pipettor, 100 to 1000 µL (VWR Catalog #4000-208, Rochester, NY), pipettor, 2 to 20 µL (VWR Catalog #4000-202, Rochester, NY), pipettor, 20 to 200 µL (VWR Catalog #4000-204, Rochester, NY), plate reader (Bio-tek Instruments Model #Elx800, Winooski, VT), PURELAB Plus Water Polishing System (U.S. Filter, Lowell, MA), refrigerator, 4°C (Forma Model #F3775, Marietta, Ohio).

**Chemicals, Reagents and Buffers** - Prostaglandin E<sub>2</sub> EIA Kit-Monoclonal 480-well (Cayman Chemical Catalog # 514010, Ann Arbor, MI), centrifuge tube, 50 mL, conical, sterile (VWR Catalog #20171-178, Rochester, NY), Dulbecco's Modification of Eagle's Medium (DMEM) (Mediatech Catalog #10-013-CV, Herndon, VA), graduated cylinder, 100 mL (VWR Catalog #24711-310, Rochester, NY), KimWipes (Kimberly

5 Clark Catalog #34256, Roswell, GA), microfuge tubes, 1.7 mL (VWR Catalog #20172-  
698, Rochester, NY), penicillin/streptomycin (Mediatech Catalog #30-001-CI, Herndon,  
VA), pipet tips for 0.5 to 10  $\mu$ L pipettor (VWR Catalog #53509-138, Rochester, NY),  
10 pipet tips for 100-1000  $\mu$ L pipettor (VWR Catalog #53512-294, Rochester, NY), pipet  
tips for 2-20  $\mu$ L and 20-200  $\mu$ L pipettors (VWR Catalog #53512-260, Rochester, NY),  
pipets, 25 mL (Becton Dickinson Catalog #7551, Marietta, OH), storage bottle, 100 mL  
(Corning Catalog #1395-100, Corning, NY), storage bottle, 1000 mL (Corning Catalog  
#1395-1L, Corning, NY), ultra-pure water (Resistance =18 megaOhm-cm deionized  
water). \_

15 **General Procedure** - EIA Buffer was prepared by diluting the contents of EIA Buffer  
Concentrate (vial #4) with 90ml of Ultra-pure water. The vial #4 was rinsed several  
times to ensure all crystals had been removed and was placed into a 100 mL storage  
bottle and stored at 4°C.\_

20 The Wash Buffer was prepared by diluting Wash Buffer Concentrate (vial #5)  
1:400 with Ultra-pure water. 0.5 ml/liter of Tween 20 (vial #5a) was then added (using a  
syringe for accurate measurement). i.e. (For one liter Wash Buffer add 2.5ml Wash  
Buffer Concentrate, 0.5ml Tween-20, and 997ml Ultra-pure water.) The solution was  
stored in a 1 liter storage bottle at 4°C.

25 The Prostaglandin E<sub>2</sub> standard was reconstituted as follows. A 200 $\mu$ L pipet tip was  
equilibrated by repeatedly filling and expelling the tip several times in ethanol. The tip was

5 used to transfer 100  $\mu$ L of the PGE<sub>2</sub> Standard (vial #3) into a 1.7 mL microfuge tube. 900 $\mu$ L Ultra-pure water was added to the tube and stored at 4°C, which was stable for ~6 weeks.

The Prostaglandin E<sub>2</sub> acetylcholinesterase tracer was reconstituted as follows. 100  $\mu$ L PGE<sub>2</sub> tracer (vial #2) was taken and mixed with 30 mL of the EIA Buffer in a 50 mL centrifuge tube and stored at 4°C. The solution should be used within five weeks.

10 The Prostaglandin E<sub>2</sub> monoclonal antibody was reconstituted as follows. 100 $\mu$ L PGE<sub>2</sub> Antibody (vial #1) was taken and mixed with 30 mL of the EIA buffer in a 50 mL centrifuge tube and stored at 4°C. This solution should be used up within 5 weeks.

DMEM with penicillin/streptomycin was prepared by adding 5 mL penicillin/streptomycin into 500 mL DMEM and stored at 4°C

15 The plate was set up as follows: Each plate contained a minimum of two blanks (B), two non-specific binding wells (NSB), two maximum binding wells (B<sub>0</sub>), and an eight point standard curve run in duplicate (S1-S8). Each sample was assayed at a minimum of two dilutions and each dilution was run in duplicate.

20 The standard was prepared as follows: Eight 1.7 mL microuge tubes were labeled as tube 1-8. 900  $\mu$ L DMEM into was put in tube 1 and 500  $\mu$ L DMEM into tubes 2-8. 100  $\mu$ L of the PGE<sub>2</sub> standard was put into tube 1 and mixed. Five-hundred microliter solution was taken from tube 1 and put into tube 2 and this process was repeated through tube 8.

25 Fifty microliters of EIA Buffer and 50 $\mu$ l DMEM were added into the NSB wells. Fifty  $\mu$ l DMEM was added to the B<sub>0</sub> wells. Fifty microliters of solution was taken from tube #8 and added to both the lowest standard wells (S8). Fifty microliters was taken from tube

5 #7 and added to each of the next two wells. Continue this through to tube #1. (Use the same pipet tip for all 8 of the standards. Make sure to equilibrate the tip in each new standard by pipeting up and down in that standard. Using a P200, add 50 $\mu$ l of each sample at each dilution to the sample wells).

10 Using the 12 channel pipetor, 50 $\mu$ l of the Prostaglandin E<sub>2</sub> acetylcholinesterase tracer was added to each well except the Total Activity (TA) and the Blank (B) wells. Using the 12 channel pipetor, 50 $\mu$ l of the Prostaglandin E<sub>2</sub> monoclonal antibody was added to each well except the Total Activity (TA), the (NSB), and the Blank (B) wells. The plate was covered with plastic film (item #7) and incubated for 18 hours at 4°C.

15 The plate was developed as follows: one 100 $\mu$ L vial of Ellman's Reagent (vial #8) was reconstituted with 50 ml of Ultra-pure water in a 50 mL centrifuge tube. It was protected from light and used the same day. The wells were and rinsed five times with Wash Buffer using a 12 channel pipettor. Two-hundred microliters of Ellman's Reagent was added to each well using a 12 channel pipettor and 5 $\mu$ l of Tracer to the (TA) well was then added to each well using a P10. The plate was covered with a plastic film and placed on orbital shaker in the dark for 60-90 minutes.

20  
25 The plate was read in the Bio-tek plate reader at a single wavelength between 405 and 420 nm. Before reading each plate, the bottom was wiped with a Kim wipe. The plate should be read when the absorbance of the wells is in the range of 0.3-0.8 A.U. If the absorbance of the wells exceeds 1.5, wash and add fresh Ellmans' Reagent and redevelop.

5

### Determination of Medium Inhibitory Concentration ( $IC_{50}$ ) -

The medium inhibitory concentration of the CO<sub>2</sub> hops extract for both COX-2 and COX-1 were assessed using CalcuSyn (BIOSOFT, biosoft.com). This statistical package performs multiple drug dose-effect calculations using the Median Effect methods described by T-C Chou and P. Talaly (Trends Pharmacol. Sci. 4:450-454). Briefly, it correlates the "Dose" and the "Effect" in the simplest possible form:  $fa/fu = (C/Cm)^m$ , where C is the concentration or dose of the compound and Cm is the median-effective dose signifying the potency. Cm is determined from the x-intercept of the median-effect plot. The fraction affected by the concentration of the test material is fa and the fraction unaffected by the concentration is fu ( $fu = 1 - fa$ ). The exponent m is the parameter signifying the sigmoidicity or shape of the dose-effect curve. It is estimated by the slope of the median-effect plot.

10

15

20

The median-effect plot is a plot of  $x = \log(C)$  vs  $y = \log(fa/fu)$  and is based on the logarithmic form of Chou's median-effect equation. The goodness of fit for the data to the median-effect equation is represented by the linear correlation coefficient r of the median-effect plot. Usually, the experimental data from enzyme or receptor systems have  $r > 0.96$ , from tissue culture or enzyme work.

### Results

25

The medium inhibitory concentration of COX-2 inhibition by the CO<sub>2</sub>-extract of hops in the RAW 264.7 cell model was 0.0.24 µg/mL (95% CI = 0.16 – 0.36). The same CO<sub>2</sub> extract of hops demonstrated a median inhibitory concentration of COX-1 production

of PGE2 of 25.5 µg/mL. Thus, a COX-1/COX-2 specificity of 106 is observed. This COX-2 specificity is 2.7-fold greater than the COX-2 specificity demonstrated for pure humulone in the TNF $\alpha$  stimulation of MC3T3 -E1 cells [Yamamoto, K. 2000. Suppression of cyclooxygenase-2 gene transcription by humulon of bee hop extract studied with reference to glucocorticoid. FEBS Letters 465:103-106]. Such a large difference in COX-2 specificity between the pure compound and the complex mixture is unexpected and constitutes a novel finding. It is unusual that a complex mixture would contain greater specific biological activity than the most active molecule. The inference is that an underlying synergy among the bioactive molecules, including humulone, is to account for such an effect.